United Therapeutics (UTHR) Could Be 15% Below Fair Value Following Its Recent Rally
United Therapeutics (UTHR) has caught investor attention after recent share price gains, with the stock up around 12% over the past week and roughly 11% over the past month.
That recent surge in United Therapeutics comes on top of a 9.04% year to date share price return. It follows a period where the 90 day share price performance had slipped 2.29%, while the 1 year total shareholder return of 18.56% and 3 year total shareholder return of 135.15% point to stronger momentum over a longer horizon.
Compare United Therapeutics' recent surge with a hand picked group of resilient healthcare and biotech players in the 31 resilient stocks with low risk scores to see how other lower risk stocks are moving.
United Therapeutics now trades around $541.62, while analyst targets cluster near $646 and some fair value models imply a much wider gap. Is the recent rally closing that valuation spread, or is it just exposing it?
Most Popular Narrative: 15% Undervalued
On the most followed view of United Therapeutics, the share price of $541.62 sits meaningfully below an implied fair value around $637.92, with that gap hinging on how its pulmonary pipeline and cash generation play out over time.
The company's innovation wave pipeline, including studies in progressive fibrosis, next-generation delivery platforms (oral, implantable), and organ manufacturing (xenotransplant/3D printing), positions United Therapeutics to benefit from the expanding focus on personalized and regenerative medicine. This focus can create new revenue streams and margin expansion opportunities as these long-horizon technologies approach clinical milestones and eventual commercialization.
See why 32 investors see United Therapeutics as 15% undervalued.
Result: Fair Value of $637.92 (UNDERVALUED)
Still, the United Therapeutics narrative relies heavily on successful pulmonary trials and regulatory outcomes, and tougher competition in PAH therapies could challenge those expectations.
Find out about the key risks to this United Therapeutics narrative.
Next Steps
If this upbeat tone around United Therapeutics has you curious rather than convinced, consider acting quickly. Pull up the numbers and pressure test the optimism for yourself using the 3 key rewards.
Looking for more United Therapeutics style investment ideas?
Do not stop with United Therapeutics. Use the Simply Wall Street Screener to quickly surface fresh opportunities that match how you like to invest and avoid missing the next setup.
- Target potential mispricing by scanning a focused set of high quality companies trading below their implied value through the 27 high quality undervalued stocks.
- Strengthen your portfolio's foundations by filtering for resilient businesses using the list of solid balance sheet and fundamentals (25 results).
- Hunt for underfollowed opportunities by zeroing in on financially sound stocks that the crowd may have overlooked with the 19 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com